(Q46113809)

English

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

scientific article published on 2 December 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

2 references

Europe PubMed Central

28 October 2022

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Heinz-Josef Lenz

2

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Robert L Ferris

1

object named as

Robert L Ferris

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

author name string

Anna Maria Trotta

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Jesús García-Foncillas

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Jeltje Schulten

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

François Audhuy

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Marco Merlano

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Gerard Milano

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

publication date

2 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

1 February 2018

1 reference

28 October 2022

Cancer Treatment Reviews

2 references

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

28 October 2022

63

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

48-60

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

copyright license

Creative Commons Attribution-NonCommercial-NoDerivatives

1 reference

28 October 2022

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CXCR3 ligands: redundant, collaborative and antagonistic functions

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenic cell death in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Innate and adaptive immune cells in the tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting CD137 enhances the efficacy of cetuximab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 regulates extrathymic regulatory T-cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complexity and challenges in defining myeloid-derived suppressor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR inhibition for recurrent or metastatic HNSCC

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic potential and challenges of natural killer cells in treatment of solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of absolute neutrophil to CD4 lymphocyte values as a marker of immunosuppression in cancer patients on cytotoxic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The consensus molecular subtypes of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for Head and Neck Squamous Cell Carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Roles of regulatory T cells in cancer immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A real-time digital bio-imaging system to quantify cellular cytotoxicity as an alternative to the standard chromium-51 release assay.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In Brief: Myeloid-derived suppressor cells in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elements of cancer immunity and the cancer-immune set point

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospects for combining targeted and conventional cancer therapy with immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29223828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CTRV.2017.11.008

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

release_hgjgbs56wjckjavswqprrfl6z4

1 reference

https://api.fatcat.wiki/v0/release/hgjgbs56wjckjavswqprrfl6z4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/29223828

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46113809&oldid=2145884117"